AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2016
Sep 23, 2016
31289_dirs_2016-09-23_b1c833c5-396a-44a6-b5f8-94c3e049f8da.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-09-22
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-09-22 | Common Stock | S | 3000.0 | $117.34 | Disposed | 122664 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.25 to $117.46, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 8
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
M&A Activity
2026
Apr 27
Annual Report
2026
Apr 21